ImmunityBio (NASDAQ:IBRX – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.
Analyst Ratings
This is a breakdown of recent ratings and target prices for ImmunityBio and Monte Rosa Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ImmunityBio | 1 | 0 | 5 | 1 | 2.86 |
| Monte Rosa Therapeutics | 1 | 1 | 8 | 1 | 2.82 |
ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 46.69%. Monte Rosa Therapeutics has a consensus price target of $27.62, suggesting a potential upside of 179.49%. Given Monte Rosa Therapeutics’ higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than ImmunityBio.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ImmunityBio | $113.29 million | 90.56 | -$351.40 million | ($0.97) | -9.98 |
| Monte Rosa Therapeutics | $123.67 million | 6.82 | -$38.63 million | ($1.76) | -5.62 |
Monte Rosa Therapeutics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ImmunityBio and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ImmunityBio | -598.55% | N/A | -51.65% |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
Volatility and Risk
ImmunityBio has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
Institutional and Insider Ownership
8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Monte Rosa Therapeutics beats ImmunityBio on 9 of the 14 factors compared between the two stocks.
About ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
